The electrochemical stability of 10 organic cations, which can be used in ionic liquids (IL), was investigated as solutes in acetonitrile (ACN). The stability of three of the salts, BenMe2EtNCl (salt III), 1-butyl-2-methyl pyrrolidium chloride (salt VI), and its structural isomer, BuMe2ProNCl (salt VII), were also compared in chloroaluminate ILs. The chloroaluminate ILs of salts VI and VII are investigated for the first time. The NaCl-neutralized ILs of salts VI and VII have melting points of 43.2 and 3.7 degrees C, respectively. The benzyl-substituted cation, salt III, was more easily reduced in ACN or as the neutral chloroaluminate IL than the alkyl-substituted cation, salt VII, due to the better leaving ability of the benzyl group. Mass spectroscopy measurements before and after electrolysis on the benzyl-substituted solutions confirmed that reduction involves the loss of an alkyl group. In ACN, salt VI was found to be the most difficult to reduce (1 mA/cm2 at -2.09 V) due to its cyclic structure. However, in the chloroaluminate IL, the pyrrolidinium cation was more easily reduced than salt III or its isomer, salt VII, resulting in an insoluble black deposit. This is consistent with the mass spectrometry data, which do not show formation of low-molecular-weight products, as in the reduction of salts III and VII. The IL of salt VII was the most stable in the presence of sodium. Sodium ions could be reduced and reoxidized with a maximum Coulombic efficiency of 94.1% versus 87.2% for salt VI. Reduction of the pyrrolidinium cation produces insoluble products, most likely through opening of the cyclic ring, and an inferior medium for sodium ion reduction compared to the benzyl- and butyl-substituted cations, even though reduction of the cation occurs at a more negative potential in acetonitrile.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1021/jp053106v | DOI Listing |
Front Immunol
January 2025
Department of Immunodermatology, National Medical Institute of the Ministry of the Interior and Administration, Warsaw, Masovian, Poland.
Linear IgA bullous dermatosis (LABD) is a rare subepidermal blistering disorder characterized by the presence of linear IgA deposits at the basement membrane zone (BMZ) by direct immunofluorescence (DIF). This entity was first described by Chorzelski and Jablonska from Warsaw Center of Bullous Diseases, Poland. The disease affects children and adults, whereby they differ in terms of clinical picture and course.
View Article and Find Full Text PDFBMC Plant Biol
December 2024
Key Laboratory of Biology and Genetic Improvement of Oil Crops of the Ministry of Agriculture and Rural Affairs, Oil Crops Research Institute of the Chinese Academy of Agricultural Sciences, Wuhan, 430062, China.
Background: Laccases (LACs) are vital plant growth and development enzymes, participating in lignin biopolymerization and responding to stress. However, the role of LAC genes in plant development as well as stress tolerance, is still not well understood, particularly in sesame (Sesamum indicum L.), an important oilseed crop.
View Article and Find Full Text PDFBioorg Chem
January 2025
Bose Institute, Department of Chemical Sciences, Block EN-80, Sector - V, Salt Lake, Kolkata 700091, India. Electronic address:
In a quest of developing carbohydrate derived anti-cancer agents, novel carbohydrate dithioacetal derivatives have been synthesized and evaluated for their potential as anti-proliferative agents against breast cancer cell lines (MCF-7 and MDA-MB-231) as well as non-cancerous kidney epithelial cell line (NKE). Total 18 compounds have been screened and 3 compounds showed promising anti-proliferative activities against cancer cells with low cytotoxicity to the normal cells using MTT assay. The mode of action of the best active compound has been proposed based on several microscopic studies.
View Article and Find Full Text PDFCureus
October 2024
Department of Anesthesiology, Uniformed Services University of the Health Sciences, Bethesda, USA.
Clin Exp Dermatol
December 2024
St John's Institute of Dermatology, Guy's and St Thomas' NHS Foundation Trust, London, UK.
Background: Epidermolysis bullosa acquisita (EBA) is a chronic mucocutaneous disease that is mediated by antibodies that bind collagen VII. The treatment of EBA can be challenging and the use of multiple immunomodulatory drugs is often required. Rituximab has been reported to be an effective treatment for recalcitrant EBA, although the evidence base for this treatment is limited to case reports and case series.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!